EX-99.1 2 tm231721d1_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

| Corporate Presentation January 2023 1 Confidential

| Forward Looking Statements This presentation and various remarks we make during this presentation contain forward - looking statements of Astria Therapeutics, Inc . (“Astria,” the “Company,” “we”, “our” or “us”) within the meaning of applicable securities laws and regulations, including statements with respect to : the Company’s projected cash runway and cash, cash equivalents and short - term investments as of 12 / 30 / 2022 ; expectations regarding the nature, timing and potential significance of the preliminary results from the Phase 1 a STAR - 0215 trial, the plans to add additional cohorts to the trial and the anticipated nature and timing of receipt of the data from such additional cohorts ; expectations regarding the timing of initiation, design and timing and nature of the anticipated proof of concept results from the planned Phase 1 b/ 2 clinical trial of STAR - 0215 ; the longer term development plans for STAR - 0215 ; the potential attributes and differentiated profile of STAR - 0215 as a treatment for HAE, including its potential best - in - class pharmacokinetic profile, potential dosing frequency, clinical benefit and those suggested by the preliminary results from the STAR - 0215 Phase 1 a trial, preclinical and pharmacokinetic modeling data ; the potential commercial opportunity for STAR - 0215 in HAE, including its potential to be a best - in - class and most patient friendly treatment option for HAE ; the need for effective treatments for HAE ; the size and anticipated growth of the HAE market ; the expected patent protection of patents directed at STAR - 0215 ; potential every six - month dosing for STAR - 0215 ; and the Company’s goal to meet the unmet needs of patients with rare and niche allergic and immunological diseases, and expand its pipeline . We use words such as "aims," “anticipate,” “believe,” “estimate,” “expect,” "goals," “hope,” “intend,” “may,” "opportunity," “plan,” “predict,” “project,” “target,” “potential,” “would,” "vision," “can,” “could,” “should,” “continue,” and other words and terms of similar meaning to help identify forward - looking statements, although not all forward - looking statements contain these identifying words . Actual results may differ materially from those indicated by such forward - looking statements as a result of various important factors, including risks and uncertainties related to : changes in applicable laws or regulations ; the possibility that we may be adversely affected by other economic, business, and/or competitive factors, including the COVID - 19 pandemic ; risks inherent in pharmaceutical research and development, such as : adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of pre - clinical studies may not be replicated in clinical studies, that the preliminary results from the Phase 1 a trial may be change once the final results are received and analyzed, that the results of early stage clinical studies may not be replicated in later stage clinical studies, the risk that we may not be able to enroll sufficient patients in our clinical trials on a timely basis, and the risk that any of our clinical trials may not commence, continue or be completed on time, or at all ; decisions made by, and feedback received from, the U . S . FDA (“FDA”) and other regulatory authorities on our regulatory and clinical trial submissions and other feedback from potential clinical trial sites, including investigational review boards at such sites, and other review bodies with respect to STAR - 0215 and any other future development candidates ; our ability to manufacture sufficient quantities of drug substance and drug product for STAR - 0215 and any other future product candidates on a cost - effective and timely basis, and to develop dosages and formulation for STAR - 0215 and any other future product candidates that are patient - friendly and competitive ; our ability to develop biomarker and other assays, along with the testing protocols therefore ; our ability to obtain, maintain and enforce intellectual property rights for STAR - 0215 and any other future product candidates ; our potential dependence on collaboration partners ; competition with respect to STAR - 0215 or any of our other future product candidates ; the risk that survey results and market research may not be accurate predictors of the commercial landscape for HAE and the anticipated position and attributes of STAR - 0215 in HAE based on its clinical data to date, pre - clinical profile, pharmacokinetic modeling and other data ; our ability to manage our cash usage and the possibility of unexpected cash expenditures ; our ability to obtain necessary financing to conduct our planned activities and to manage unplanned cash requirements ; the risk that our final audited cash, cash equivalents and short - term investments as of 12 / 30 / 2022 may differ materially from the preliminary and unaudited amount reported in this presentation ; the risks and uncertainties related to our ability to recognize the benefits of any additional acquisitions, licenses or similar transactions ; and general economic and market conditions ; as well as the risks and uncertainties discussed in the “Risk Factors” section of our Annual Report on Form 10 - K for the period ended December 31 , 2021 , and in other filings that we may make with the Securities and Exchange Commission (“SEC”) . These forward - looking statements should not be relied upon as representing our view as of any date subsequent to the date of this presentation, and we expressly disclaim any obligation to update any forward - looking statements, whether as a result of new information, future events or otherwise, except as required by law . This presentation contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry . This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates . In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk . 2

| Investment Highlights 3 Astria (Nasdaq: ATXS) is developing differentiated therapeutics for patients with rare and niche allergic and immunological diseases Our lead program, STAR - 0215 , is a monoclonal antibody inhibitor of plasma kallikrein for the preventative treatment of Hereditary Angioedema (HAE) • STAR - 0215 has shown early proof of concept for its target profile: long - acting preventative therapy, best - in - class PK profile, and dosing once every 3 months or less frequently • HAE market is large and growing, expected to reach $4.5B by 2027 1,2 Pursuing opportunities to expand our pipeline in allergic and immunological diseases Cash, cash equivalents and short - term investments of $226M 3 Expected cash runway through H1 2025 based on current operating plan 1. Analyst consensus forecasts compiled by Clarivate’s Cortellis , Astria company research and analysis 2. Company - reported sales (Takeda, CSL Behring, Pharming, BioCryst ) 3. As of 12/31/2022, unaudited and preliminary Initiating Phase1b/2 ALPHA - STAR trial in HAE patients, expected in Q1 2023 with initial proof of concept results expected by mid - 2024

| Hereditary Angioedema (HAE): A Rare, Disfiguring, and Potentially Life - Threatening Disease 4 1. Zuraw BL. N Engl J Med. 2008;359:1027 - 36. 2. Busse, P.J. et al. N Engl J Med. 2021; 132 - 150. 3. Lumry , W.R. Front Med. 2018; 5, 22. 4. Aygören - Pürsün , E. et.al. Orphanet j Rare Dis. 2018; 13:73. Rare genetic disorder charactered by severe, unpredictable, sometimes life - threatening swelling 1 Affects <8,000 in the U.S. and <15,000 in Europe, 2, 3, 4 average age of onset is 11 years old 5 Standard of care has evolved to both on - demand and preventative treatments with room for improvement 5. Bork K, et al. Am J Med. 2006;119;267 - 274. 6. Images obtained by haeimages.com

| Global HAE Treatment Market is Substantial and Growing 5 1. Company - reported sales (Takeda, CSL Behring, Pharming, BioCryst ) 2. Analyst consensus forecasts compiled by Clarivate’s Cortellis , Astria company research and analysis. 3. Zanichelli A. Clin Transl Allergy. 2018: doi : 10.1186/s13601 - 018 - 0229 - 4 $4.5B 2021 HAE Market 1 2027 Estimated HAE Market 1,2 HAE Treatment $2.3B Preventative On - Demand The HAE market is expected to nearly double by 2027 1,2 , driven by: • Patients being diagnosed earlier 3 • More patients taking preventative treatments 4 • Geographic expansion for currently available therapies 5 4. Astria company research and analysis 5. Company - reported expectations (Takeda, CSL Behring, BioCryst )

| Approved and Late - Stage Preventative HAE Treatments 6 *Efficacy quoted as reduction in mean attack rate vs placebo; data from respective products’ Prescribing Information 1,2,3,7 . 1. CINRYZE Prescribing Information, 2021. 2. HAEGARDA Prescribing Information, 2020. 3. TAKHZYRO Prescribing Information, 2018. 4. Center for Drug Evaluation and Research. NDA/BLA Multidisciplinary Review and Evaluation NDA 214094. Washington DC: CDER (US); 2020. Product Mechanism of Action Administration Mean Attack Reduction * % of Attack - Free Patients CINRYZE Plasma derived C1 - INH 2x/week 52% 18% (12 weeks) 1 HAEGARDA Plasma derived C1 - INH 2x/week 88% 40% (16 weeks) 2 TAKHZYRO (lanadelumab) Plasma kallikrein inhibitor 1 - 2x/month 73 - 87% 31 - 44% (26 weeks) 3 ORLADEYO (berotralstat) Plasma kallikrein inhibitor 1x/day 30 - 44% 2 - 8% (24 weeks) 4 5. CSL Behring, 2022 Aug 17, Press release. https://www.cslbehring.com/newsroom/2022/positive - top - line - phase - 3 - results - for - garadacimab 6. IONIS 2021 Nov 18, Press Release. https://ir.ionispharma.com/news - releases/news - release - details/ionis - initiates - phase - 3 - clinical - program - donidalorsen - patients 7. ORLADEYO Prescribing Information 2020. Approved Therapies Program Mechanism of Action Administration Development Phase Efficacy garadacimab Factor XIIa inhibitor 1x/month 3 TBD 5 donidalorsen Prekallikrein inhibitor 1x/1 - 2 months 3 TBD 6 Late - Stage Development Programs There remains a need for an effective, infrequent treatment that can help normalize the lives of people with HAE

| STAR - 0215’s Target Efficacy and Dosing is Compelling to Surveyed HAE Treatment Providers and Patients 7 Survey respondents were shown a blinded product profile that included: a monoclonal antibody inhibitor of plasma kallikrein t hat helps prevent HAE attacks by suppressing the pathway that generates bradykinin and causes excessive swelling, efficacy on par with current subcutaneous therapies, dosing once every 3 mon ths or longer 1. Astria proprietary blinded qualitative market research study (2021) with 20 HAE treatment providers (screened for those tr eat ing at least 5 Type 1 & 2 HAE patients per year). 2. Astria proprietary blinded quantitative market research study (2022) with 101 HAE patients recruited by HAEA patient organization. P ati ents were screened for those currently taking preventative HAE therapy or having at least 1 attack every 3 months. Not at all likely to prescribe Extremely likely to prescribe 6.5 Surveyed Prescribers Were Highly Motivated to Prescribe a Product with STAR - 0215’s Target Profile 1 1 7 6 5 4 3 2 Willingness rated on a scale where “0” indicates “Not at all willing,” and “10” indicates “Extremely willing.” Satisfaction with current treatment rated on a scale where “0” indicates “Not at all satisfied,” and “10” indicates “Extremely satisfied.” Ratings of 8 - 10 grouped as “Very Satisfied.” All Surveyed Patients Were Willing to Try a Product with STAR - 0215’s Target Profile 2 All Patients (n=101) Patients Taking Only On- Demand Medication (n=16) Patients Very Satisfied with Current Preventative Therapy (n=69) 31% 50% 28% 69% 50% 72% 0% 20% 40% 60% 80% Not Willing (rated 0-2) 0% Somewhat Willing (rated 3-7) Very Willing (rated 8-10) Not Willing (rated 0-2) Somewhat Willing (rated 3-7) Very Willing (rated 8-10) Not Willing (rated 0-2) Somewhat Willing (rated 3-7) Very Willing (rated 8-10) 0% 0% P a t i e n t W i l l i n g n e s s t o T r y a T h e r a p y w i t h S T A R - 0 2 1 5 ’ s T a r g e t P r o f i l e

| STAR - 0215 Potential for Best - in - Class Profile in HAE 8 1. If this application is nationalized in PCT member states ex - U.S., the term of any resulting patents would also be to 2042, ex clusive of any available term extensions. Novel CDRs with patent pending Fc engineered with YTE modifications for half - life extension Potent inhibition of plasma kallikrein activity High selectivity for plasma kallikrein Formulated to reduce pain Preclinical Profile of STAR - 0215 Encouraging preliminary clinical results Demonstrated high potency for plasma kallikrein and long plasma half - life Differentiated profile Potential benefits include long duration without breakthrough attacks and infrequent SC dosing - once every 3 months or longer Trusted modality To provide patients with improved quality of life Astria wholly owns an international patent application directed to STAR - 0215. If nationalized in the U.S. and granted, the pate nt would expire in 2042, excluding any potential patent term extension 1 High concentration formulation supports SC dosing

| STAR - 0215 Phase 1a Trial 9 • Randomized, double - blind 1 , placebo - controlled ▪ Healthy adult subjects ▪ 3 single ascending doses, delivered SC ▪ 6 active to 2 placebo randomization • Preliminary data include safety (84 days for 3 cohorts), PK and PD (84 days for cohorts 1 and 2; 56 days for cohort 3) COHORT 1 2 3 100 mg SC TIMELINE 300 mg SC 600 mg SC SC Administration Follow - Up (Day 84) End of observation period (Day 224) 1. As of this data cut - off, treatment assignments remain blinded. Presented PK, PD, and safety data are delinked from individual s ubject identifier. SC = subcutaneous; PK = pharmacokinetic; PD = pharmacodynamic Preliminary, blinded data, cut - off Dec 5, 2022 Phase 1a Trial Design Schematic

| 10 STAR - 0215 1 : • 8 (32%) subjects (STAR - 0215 or placebo) had related TEAEs • No SAEs and all related TEAEs were mild (Grade 1) and resolved. No Grade 2, 3, or 4 TEAEs. • 6 subjects had ISRs (all mild), most commonly site redness; no reports of pain TEAE= Treatment - emergent adverse event; ISR = injection site reaction; SAE = serious adverse events 1. Other related TEAEs were headache (1 subject) and unexplained weight gain (1 subject), both in Cohort 1 (100 mg). There were no clinically relevant changes in vital signs, ECG parameters, or laboratory values. 15 Grade 1 (mild) ISRs occurred in 6 subjects, including erythema (site redness), pruritus, swelling and inflammation. No clinically relevant changes in liver enzymes or coagulation parameters. No deaths, or adverse events leading to study discon tinuation. Results will be finalized after the end of the observation period 2. TAKHZYRO US Prescribing Information, Feb 2022. The comparison presented between STAR - 0215 and lanadelumab represents a cross - trial comparison and does not involve data from a head - to - head clinical trial Results Suggest that STAR - 0215 is Well - Tolerated and has a Favorable Safety Profile 3 - Month Timepoint Blinded Adverse Event Results Lanadelumab 2 : The most common adverse reactions associated with lanadelumab are: • Injection site reactions, most commonly pain (52%) • Upper respiratory tract infection (29%) • Headache (21%)

| 11 Results Show STAR - 0215 has a Potential Best - In - Class PK Profile Results will be finalized after the end of the observation period 1. Chyung et al 2014. Weight (SD) in this dose cohort = 83.08 (9.459) kg. Mean dose is 249.2 mg SC. The comparison presented between STAR - 0215 and lanadelumab represents a cross - trial comparison and does not involve data from a head - to - head clinical trial. STAR - 0215 : • Estimated half - life is up to 110 days , >5 times longer than lanadelumab • Rapid achievement of maximum concentration • Sustained concentrations at levels consistent with clinical benefit

| Results Show Rapid and Sustained STAR - 0215 Concentrations After Single Subcutaneous Doses 12 Mean (SD) concentrations over time Results will be finalized after the end of the observation period STAR - 0215 : • Concentrations are proportional to dose • Long elimination phase consistent with YTE - modification • Estimated half - life of up to 110 days

| Modeling Supports Potential for Clinical Benefit with Infrequent Dosing 13 1. Kaufman 1991 June 15. Blood 77(12): 2660 - 2667 2. Wang et al. Clin Transl Sci. 2020 Nov, 13(6): 1208 - 1216. doi 10 - 1111/ cts . 12806 Epub 2020 May 26. 3. Ecallantide EMA Assessment Report. 2011 June 23. EMA/CHMP/476618/2011 Simulated Human PK Profile of a Possible Clinical Dose Regimen 600 mg 300 mg 300 mg 300 mg Days 1,2,3

| Target Engagement is Assessed by Change in FXIIa - Activated cHMWK 14 *p = 0.001; **p = 0.003 HMWK = high molecular weight kininogen cHMWK = cleaved high molecular weight kininogen FXIIa = activated Factor XII PLASMA KALLIKREIN INHIBITION BY STAR - 0215 Bradykinin MEASURED BY PD ASSAY cHMWK + HMWK FXIIa Plasma kallikrein Pre kallikrein Blood FXlla Biomarker Assay Plasma kallikrein activated by FXIIa to cleave HMWK Inhibition of plasma kallikrein by STAR - 0215 to reduce cleavage of HMWK 1. Chyung et al, 2014 HV = healthy volunteer

| Results Show STAR - 0215 Achieves Sustained Inhibition of Plasma Kallikrein 15 No significant changes at any timepoints with placebo or 100 mg STAR - 0215 Results will be finalized after the end of the observation period 1. Wang et al. Clin Transl Sci. 2020 Nov, 13(6): 1208 - 1216. doi 10 - 1111/ cts . 12806 Epub 2020 May 26. The comparison presented between STAR - 0215 and lanadelumab represents a cross - trial comparison and does not involve data from a head - to - head clinical trial • Levels of inhibition achieved ( 40 - 60% decreases in FXIIa - activated cHMWK ) are consistent with the levels shown to prevent attacks in patients 1 • Single dose of 300 mg leads to significant d urable inhibition of plasma kallikrein observed through 3 months 0 14 28 42 56 70 84 0 20 40 60 80 Day Inhibition of FXIIa-Activated HMWK Cleavage (Percent) STAR-0215 (600 mg) STAR-0215 (300 mg) Lanadelumab (3 mg/kg)

| 1. This cohort is expected to commence after a safety assessment of Cohort 1 Proposed ALPHA - STAR Trial Design Open - Label Single and Multiple Dose Phase 1b/2 POC Clinical Trial in HAE Single Dose, n =4 8 - week Run - In Planned Phase 2 Long - Term Open - Label Trial (LTOL) 450 mg, 6 - month follow - up Multiple dose, n ≤14 600 mg 300 mg, 6 - month follow - up Dosing is 3 months apart 8 - week Run - In PRIMARY: Safety and tolerability SECONDARY: Change from baseline in HAE attacks, PK, and PD EXPLORATORY: Angioedema Quality of Life Patient Reported Outcome Assessment 16 COHORT 1 COHORT 2 1 PROOF OF CONCEPT ENDPOINTS: Doses may change based on emerging data

| Overview of the Expected Clinical Development Plan Long - Term Open Label Trial Phase 3 Pivotal Trial in HAE Patients Initial results Q4 ‘23 Phase 1a, SAD - Healthy Subjects Initial results Mid ‘24 New cohorts Q1 ‘23 Initiate Q1 ‘23 Initiate H2 ‘23 ALPHA - STAR Phase 1b/2 POC Trial - HAE Patients PHASE 1A to POC to PIVOTAL TRIAL Explore potential for 6 - month dosing Demonstrate POC in HAE Patients 17

| 18 1. As of 12/31/2022, unaudited and preliminary 2. As of 12/30/2022 2023 2024 PHASE 1A • Phase 1a 3 - month results at scientific conference • Initiate additional Phase 1a cohorts to evaluate 6 - month dosing PHASE 1B/2 Q1 • Phase 1b/2 ALPHA - STAR trial initiation PHASE 1A Q4 Preliminary results from 6 - month cohorts Astria (Nasdaq ATXS) Well - Positioned for the Future Expected Upcoming Milestones PHASE 1B/2 Proof - of - concept results in HAE patients from the ALPHA - STAR trial Mid • Cash, cash equivalents and short - term investments of $226M 1 • Expected cash runway through H1 2025 based on current operating plan • Common stock outstanding on an as - converted basis 2 : 32.7M o 27.5M common stock outstanding and 5.2M series X preferred 2023 2023 2024